Curta

I was happy to see that our estimates for net prices of GLP-1s published earlier this year in Obesity were used by the Congressional Budget Office to estimate budgetary effects of the coverage of anti-obesity medications in Medicare I was curious to see their estimates for reductions in prices with negotiation. CBO estimates annual net prices across the class will decrease from $5,900/year to $4,000/year after Wegovy is negotiated. However, it is difficult to retro-calculate how much of a price decrease they estimate for Wegovy with negotiation, because: 1-These are averages across the entire class, and it is unclear what is the breakdown of utilization projected for each drug 2-CBO expects "that the reduction in the price of semaglutide will affect the prices of other AOMs, such as Zepbound" 3-This figure represents "total payments to Part D plans, after subtracting rebates, statutory discounts, and beneficiaries’ cost-sharing amounts and adjusting for LIS federal subsidies" (important to bear in mind in interpretation) Since this was probably not the most helpful post, I will end with a hopefully more helpful remainder - the weighted average net price of Ozempic / Rybelsus in 2023 (before tirzepatide entry!) will set the ceiling for the negotiation of Ozempic / Rybelsus /Wegovy https://lnkd.in/ezNBEQWG Sean Sullivan UC San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences The CHOICE Institute

Peterson Health Technology Institute (PHTI)'s 3rd assessment focuses on digital hypertension management solutions. Through our collaboration with PHTI as an independent evaluation partner, Curta assessed the clinical and economic impact of these technologies, including a systematic literature review and budget impact assessment, using the ICER-PHTI Assessment Framework. Certain digital hypertension management solutions can improve clinical outcomes, but not all approaches are equally effective. The report guides payers, providers, and innovators on the adoption and development of high-value digital hypertension solutions. Read the full report: https://lnkd.in/eenxUymt #HealthCosts #Hypertension #HealthTech

See you at #ISPOREurope! Catch up with Sean Sullivan, Scott Ramsey, Lisa Bloudek or Brian Bloudek.

Congratulations to all honorees and especially Inmaculada (Inma) Hernandez. Well deserved! ??

?? Exciting News for Curta Enthusiasts! ?? We’re thrilled to announce the launch of our Curta subsite, Story.Curta.com, dedicated to the fascinating story behind the Curta Calculator and its inventor, Curt Herzstark ?? Whether you’re a long-time fan or just curious about this remarkable mechanical device, check it out! Shout-out to Marco Flammini for his brilliance in bringing the Curta story to life. https://lnkd.in/dtNN4dz3 #CurtaCalculator #NewWebsite #MechanicalEngineering #MathNerds #Innovation #MathGrenade #HEOR #Curta

Meanwhile, in Vegas… Catch some of Curta's research in the fabulous Las Vegas at AMCP NEXUS 2024! Connect with Ashley Kang, Sean Sullivan, Elizabeth Brouwer, PhD MPH or Scott Ramsey to learn more about these projects. #AMCPNexus #MeanwhileinVegas

?? Exciting News! ?? We are thrilled to announce the launch of our brand new website! www.Curta.com ?? We’re proud to share a fresh and user-friendly experience and to showcase the tremendous growth and accomplishments of Curta over the past few years. ?? Explore our new company page to learn about our services, meet our team, and access valuable resources. We invite you all to check it out. Your support means the world to us. Thank you for being a part of our journey! ?? #WebsiteLaunch #HEOR #Innovation #ThankYou #Curta

Our regular column where we select the latest published from September 2024 across the spectrum of?#RWE and?#HTA. This month, we feature: - Why is the market design for innovative pharmaceuticals not well understood? Francisco Oliven?a,?Jose Diaz,?Sreeram Ramagopalan and?Lou Garrison?Jr - Development of stakeholder-informed recommendations for inclusion of family spillover effects in health technology assessment. David Campbell,?Rajshree Pandey,?Lisa Bloudek,?Josh Carlson,?Christopher Wallick,?David Veenstra and?Stacey Kowal - Analysis of factors associated with use of real-world data in single technology appraisals of cancer drugs by the National Institute for Health and Care Excellence. Jiyeon Kang and?John?Cairns - Development of a Canadian guidance for reporting real-world evidence for regulatory and health-technology assessment (HTA) decision making. @Mina Tadrous, Theresa Aves, Christine Fahim and colleagues - PMDA Perspective on RWD/RWE Utilization for Regulatory Purposes Including Assessment on the Impacts of Regulatory Actions and Safety Risk of a Drug at Postmarketing Stage. Kazuhiro Kajiyama,?Maki Komamine,?Naoya Horiuchi,?Toyotaka Iguchi,?Yoshiaki Uyama - Adopting a framework for rapid real-world data analyses in safety signal assessment. Lu Wang, Negar Golchin, Stephanie von Klot, Claudia A Salinas, Katrin Manlik, Vaishali Patadia, PhD, MBA, MPH, Mary K Miller, Julius Asubonteng, Rachel McDermott, Julie Barberio & Geoffrey Gipson - Examining the effect of missing data and unmeasured confounding on external comparator studies: case studies and simulations. Gerd Rippin, Héctor Sanz, Wilhelmina E Hoogendoorn, Nicolás M Ballarini, Joan A Largent, Eleni Demas, Douwe Postmus, Theodor Framke, Lukas M Aguirre Dávila, Chantal Quinten & Francesco Pignatti - Analytical methods for comparing uncontrolled trials with external controls from real-world data: a systematic literature review and comparison to European regulatory and health technology assessment practice. Milou A Hogervorst, Kanaka V Soman, Helga Gardarsdottir, Wim Goettsch & Lourens T Bloem - Drugs anticipated to be selected for the Medicare Drug Price Negotiation Program in 2025. Emma M Cousin, Sean Sullivan, Ryan N Hansen, Nico Gabriel, Ayuri S Kirihennedige & Inmaculada (Inma) Hernandez Read at The Evidence Base? #heor #healtheconomics #outcomesresearch #rwe #rwd #realworldevidence #realworlddata #marketaccess #pharma #biopharma #medicalaffairs #regulation #regulatoryaffairs #hta #healthtechnologyassessment #healthdata #healthequity #healthpolicy

If you’re headed to the #ASCOQualityCareSymposium in #SanFrancisco this weekend, be sure to stop by our poster on “Real-world molecular testing patterns in primary advanced or recurrent endometrial cancer” co-authored by Scott Ramsey, Yilin Chen, Troy Williams, and Josh Carlson ? #healtheconomics #HEOR #Curta #endometrialcancer #RWE

Curta researchers David Campbell, Rajshree Pandey, Lisa Bloudek, and David Veenstra are grateful for the opportunity to and proud to have contributed to this work.